Learning Objectives: 1. Understand the updated nomenclature of steatotic liver disease (SLD) and differentiate between its subcategories, including MASLD, ALD, MetALD, and cryptogenic SLD. 2. Evaluate...
Shyamal Sheth
Where are we at with a medication to treat MASH cirrhosis?
Chiara Maruggi
What should I do for an older patient who is referred for liver fibrosis but does not appear to have any clear liver disease?
Richie Manikat
MASLD Metabolic dysfunction-associated steatotic liver disease (MASLD) refers to the presence of hepatic steatosis when no other causes for secondary hepatic fat accumulation are present, and patients...
Anjiya Shaikh
If I want to diagnose advanced fibrosis in my patient, how much better is MRI with FIB-4 compared to Fibroscan with AST?
Now that the FDA has rejected obeticholic acid for NASH, what WAS the evidence supporting its use?
Podcast URL Show Notes There are new NASH Guidelines and we're gonna talk about them. Who better to chat with than lead author Dr. Mary Rinella? Probably nobody! But first, the precarities of being an...
Adam Winters
Alex Vogel
GLP-1 agonists are approved for the treatment of diabetes and for obesity. Why are patients with non-alcoholic fatty liver disease (NAFLD) suddenly being prescribed GLP-1 agonists and what are the...
Melissa Kaltenbach
Does weight loss really help with managing NASH?
https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.32244 More benefits of good glycemic control in patients with NAFLD!
Enter your email here and receive monthly newsletters with new LFN material.
Registration failed. Please try again later.
